Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 16 Oct 2018
New checks to crack down on free prescription fraud
14 October 2018 - Patients claiming free prescriptions in England face checks before medicine is issued in an effort to ...
Posted by Michael Wonder on 11 Oct 2018
ABPI tells MPs Brexit deal on medicines regulation ‘urgently needed’
11 October 2018 - Pharmaceutical companies “are doing everything in their power” to minimise disruption to the supply of medicines ...
Posted by Michael Wonder on 10 Oct 2018
XLH patients to get routine access to first new therapy in 30 years
10 October 2018 - For the first time in more than 30 years children and young adults in England and ...
Posted by Michael Wonder on 08 Oct 2018
NICE expands backing for Pfizer’s Mylotarg
8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with ...
Posted by Michael Wonder on 05 Oct 2018
Gilead strikes deal with NHS England on CAR-T Yescarta
5 October 2018 - NHS England claims adult leukaemia access is first in Europe. ...
Posted by Michael Wonder on 05 Oct 2018
MHRA consults on new regulatory framework for ‘no-deal’ scenario
5 October 2018 - The Medicines and Healthcare products Regulatory Agency has launched a consultation seeking views on how its ...
Posted by Michael Wonder on 04 Oct 2018
NICE publishes draft guidance for idelalisib
4 October 2018 - The Department of Health and Social Care has asked the NICE to produce guidance on using idelalisib ...
Posted by Michael Wonder on 04 Oct 2018
NICE OK's Pfizer's Xeljanz for new indication
3 October 2018 - Xeljanz has been recommended by NICE for adults with psoriatic arthritis. ...
Posted by Michael Wonder on 03 Oct 2018
Preliminary NICE ‘no’ for Takeda’s Alunbrig
3 October 2018 - Draft guidelines from the NICE do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig. ...